Preliminary Anti-tumour activity of mTor kinase inhibitor in advanced tumours
Study identifier:D1600C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of the m-Tor Kinase Inhibitor AZD8055 using Intermittent Dosing Schedules in Patients with Advanced Solid Malignancies and Lymphomas
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8055
Sex
All
Actual Enrollment
63
Study type
Interventional
Age
18 Years +
Date
Study Start Date: -
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 May 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD8055 Oral tablet, single dose on Day 1, followed by a 48 hour – 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days. |
Contacts
Investigators
Principal Investigator
Ian Smith
AstraZeneca R&D
